» Authors » Michael A Heathman

Michael A Heathman

Explore the profile of Michael A Heathman including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 4
Citations 84
Followers 0
Related Specialty
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Aruldhas B, Quinney S, Overholser B, Heathman M, Masters A, Ly R, et al.
CPT Pharmacometrics Syst Pharmacol . 2021 Aug; 10(10):1183-1194. PMID: 34435753
Methadone is a synthetic opioid used as an analgesic and for the treatment of opioid abuse disorder. The analgesic dose in the pediatric population is not well-defined. The pharmacokinetics (PKs)...
2.
Geiser J, Heathman M, Cui X, Martin J, Loghin C, Chien J, et al.
Clin Pharmacokinet . 2015 Oct; 55(5):625-34. PMID: 26507721
Background And Objective: Dulaglutide is a long-acting glucagon-like peptide-1 receptor agonist administered as once-weekly subcutaneous injections for the treatment of type 2 diabetes (T2D). The clinical pharmacokinetics of dulaglutide were...
3.
Ernest 2nd C, Heathman M, Wrishko R
J Clin Pharmacol . 2009 Jul; 49(8):973-83. PMID: 19602721
Prasugrel is a thienopyridine prodrug that is metabolized to an active metabolite (Pras-AM), which inhibits adenosine diphosphate (ADP)-induced platelet aggregation. The study objective was to describe a multilinear regression correlation...
4.
Chien J, Friedrich S, Heathman M, De Alwis D, Sinha V
AAPS J . 2005 Dec; 7(3):E544-59. PMID: 16353932
Pharmacokinetic (PK) and pharmacodynamic (PD) modeling and simulation (M&S) are well-recognized powerful tools that enable effective implementation of the learn-and-confirm paradigm in drug development. The impact of PK/PD M&S on...